Prostate Cancer Screening Tests

Immunoassay tests for prostate-specific antigen detection in patient samples. These products support prostate cancer screening and monitoring.

Laboratory tests measuring tumor markers and molecular characteristics to guide breast cancer treatment selection.

HPV and cytology-based testing systems for early detection of cervical cancer and precancerous lesions.

A series of RNA-based diagnostic tests designed for early cancer screening and detection. These tests support the identification of cancer biomarkers for early intervention and patient management.

In vitro diagnostic tests for quantification of tumor-associated biomarkers in patient specimens. Supports cancer screening, diagnosis, and therapeutic monitoring protocols.

A rapid diagnostic test for the detection of cancer and inflammation markers at early stages. These tests provide an affordable screening tool for regular monitoring of such markers to support effective treatment of cancer and inflammatory conditions.

Diagnostic tests for prenatal screening and maternal health assessment including genetic and biochemical markers. Utilized for comprehensive obstetric care and fetal anomaly detection.

High-sensitivity rapid diagnostic tests designed for clinical screening applications. Offer maximum reliability for initial detection of infectious diseases and health conditions.

Chemiluminescence immunoassay kits for tumor marker detection and cancer screening. Provides diagnostic support for oncology applications in clinical laboratories.

A non-invasive, urine-sample-based diagnostic kit for prostate cancer detection and risk assessment. The kit utilizes PSA N-glycosylation analysis to detect asparagine-linked carbohydrates of PSA, providing comprehensive clinical insights into prostate cancer-related alterations. It employs recombinant antibody technology to ensure selectivity and cost-effectiveness, and is designed for simplicity, requiring no specialized or highly skilled operator personnel. The diagnostic method significantly reduces false-positive rates compared to conventional serum PSA tests.

Biomarker and diagnostic tests for colorectal cancer screening and detection. These products support early identification and management of colorectal cancer.

Rapid diagnostic tests for tumor marker detection, enabling quick identification of cancer-related biomarkers in clinical specimens. These tests support oncology screening and patient monitoring through accelerated processing times without compromising diagnostic accuracy.